cell-free DNA
Delfi Diagnostics Tags Lung Cancer as First Target for Fragmentation-Based Liquid Biopsy Tech
Premium
Based on promising early results, the company is now conducting a larger case-control study to lock in a classifier for prospective validation in an intended-use population.
The move opens the first non-oncology application for Oncocyte, which acquired the relevant cell-free DNA technology in its merger with Chronix this April.
The liquid biopsy test compares fragments of cfDNA to a reference database of more than 1,400 microbial pathogens to determine infection.
The company believes its molecular counting technology can offer improved sensitivity for advanced cancer genotyping and longitudinal monitoring of response to therapy.
The firm expects to replace its current screening assay with the methylation test following regulatory clearance from the country's Ministry of Food and Drug Safety.